Skip to main content

Table 3 Comparison between 4 weeks pre- and 4 weeks post-TMS as regards clinical data of migraine, MIDAS, and serum levels of neurokinin A in group A (migraine without aura)

From: Repetitive transcranial magnetic stimulation as a prophylactic treatment in migraine

  Without aura Test value P value
Pre-TMS, no. = 30 Post-TMS, no. = 30
Neurokinin A serum level Mean ± SD 24.26 ± 2.38 12.44 ± 2.94 − 4.782 < 0.001
Range 19.38–27.93 9.32–25.45
No. of headache attacks (days per month) Median (IQR) 17.50 (16.00–25.00) 6.00 (2.00–8.00) − 4.786ǂ < 0.001
Range 7.00–27.00 0.00–25.00
Duration of individual attack (hours) Median (IQR) 15.63 (12.75–18.25) .25 (0.13–0.38) − 4.762ǂ < 0.001
Range 4.75–42.00 0.00–19.50
No. of pills (per month) Median (IQR) 27.00 (15.00–33.00) 0.00 (0.00–2.00) − 4.683ǂ < 0.001
Range 0.00–79.00 0.00–33.00
Pain intensity Median (IQR) 7.50 (7.25–7.75) 1.75 (0.75–2.50) − 4.708ǂ < 0.001
Range 5.25–8.75 0.00–7.75
MIDAS score Median (IQR) 30.50 (23.00–39.00) 2.00 (0.00–5.00) − 4.783ǂ < 0.001
Range 6.00–57.00 0.00–50.00
  1. P value > 0.05, non-significant (NS); P value < 0.05, significant (S); P value < 0.001, highly significant (HS)
  2. Paired t test
  3. ǂWilcoxon’s rank test